儿童代谢功能障碍相关脂肪性肝病
儿童MASLD是儿童慢性肝病最常见病因,10%患儿存在进展期纤维化。活检仍是诊断分期的金标准,MRI质子密度脂肪分数和磁共振弹性成像分别是最可靠的无创脂肪变和纤维化评估方法。目前儿童无可用药物治疗,亟需儿科临床试验。
要点
- MASLD影响约十分之一儿童,与早亡风险增加相关。
- 10%患儿存在进展期纤维化,活检仍为诊断分期最准确方法。
- 低游离糖饮食有望减少脂肪变并降低丙氨酸氨基转移酶。
核心结论
- MASLD是影响约十分之一儿童的复杂疾病,与早亡风险增加相关,目前儿童无可用药物治疗,亟需更多专门研究和儿科临床试验。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- MASLD患儿中10%存在进展期纤维化。
- 活检仍是诊断和分期最准确的方法,MRI质子密度脂肪分数和磁共振弹性成像分别是最可靠的无创脂肪变和纤维化评估方法。
- MASLD与2型糖尿病、高血压、血脂异常、骨密度降低、阻塞性睡眠呼吸暂停、焦虑和抑郁等多种共病相关。
- 新出现的数据表明6岁以下儿童也可存在脂肪变,此前认为罕见。
- PNPLA3基因与脂肪性肝病和脂肪性肝炎风险和严重程度相关的证据最多。
关键数值与推荐
- 低游离糖饮食有望减少脂肪变并降低丙氨酸氨基转移酶(肝炎症的替代标志物)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 目前儿童无可用药物治疗,亟需儿科临床试验。
- 需要更多专门针对儿童的研究以加深对本病的理解并寻找有效治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is the most common cause of chronic liver disease in children. MASLD encompasses a spectrum of liver disease and can be severe, with 10% of affected children presenting with advanced fibrosis. While biopsy remains the most accurate method for diagnosing and staging the disease, MRI proton density fat fraction and magnetic resonance elastography are the most reliable non-invasive measures for assessing steatosis and fibrosis, respectively. MASLD is associated with multiple comorbidities including type 2 diabetes, hypertension, dyslipidaemia, decreased bone mineral density, obstructive sleep apnoea, anxiety and depression. Currently, there are no pharmacological treatments available for children, highlighting the urgent need for paediatric clinical trials. A diet low in free sugars is promising for reducing steatosis and decreasing alanine aminotransferase, a surrogate marker for hepatic inflammation. Emerging data indicate that steatosis can be present in children under 6 years of age, which was previously considered rare. The intricate interplay of genetics may inform future therapeutics and prognostication, with the PNPLA3 gene showing the most evidence for association with the risk and severity of steatotic liver disease and steatohepatitis. MASLD is a complex disease affecting one in ten children and is associated with increased early mortality risk. More dedicated studies are needed in children to advance our understanding of this disease and find effective treatments.
引用
- Goyal NP, Xanthakos S, Schwimmer JB, et al. Metabolic dysfunction-associated steatotic liver disease in children. Gut. 2025. PMID: 39848671. doi:10.1136/gutjnl-2023-331090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。